New PhIII gives Esperion's CEO a chance to push back against a legion of critics — but can he win back investors?
Esperion $ESPR would like to have back its rep for owning a cholesterol drug designed to hit a sweet spot in the market — without any unsavory safety issues that could persuade regulators to require an expensive and lengthy cardio outcomes study ahead of a marketing approval.
To that end, CEO Tim Mayleben is rolling out a fresh battery of data from their third pivotal study of bempedoic acid. And they want you to believe as they do: That the consistent ability to cut LDL — in this case by demonstrating a familiar 23% drop, with a 25% lowering in high-sensitivity C-reactive protein — tied in to no new fatalities (whew) and what they insist is a clean safety profile should be widely applauded.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.